22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: V-region immunoglobulin-containing suppressor of T cell activation (VISTA); programmed cell death 1 (PD-1; PDCD1; CD279); programmed cell death 1

Cancer INDICATION: Cancer Mouse studies suggest combining mAbs against VISTA and PD-1 or PD-L1 could help treat cancer. In mice, double-knockout of VISTA and PD-1 increased T cell responses to non-self antigens compared with single-knockout of either...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer V-region immunoglobulin-containing suppressor of T cell activation (VISTA) Cell culture and mouse studies suggest inhibiting VISTA...
08:00 , Nov 5, 2012 |  BioCentury  |  Emerging Company Profile

ImmuNext: New VISTAs

ImmuNext Inc. has developed an antagonist of VISTA, a ligand that negatively regulates T cells similar to better known members of the B7 family of proteins. But targeting VISTA could be safer than targeting other...